Treatment for Alcohol Drinking

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alcohol Drinking+8 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of reducing alcohol consumption for 30 days on behavioral and health functions, and how these changes last for up to 90 days. The study will also identify barriers and facilitators related to drinking reduction.

Eligible Conditions
  • Alcohol Drinking
  • Inflammation
  • Liver Diseases
  • HIV Infections
  • Neurocognitive Dysfunction

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Baseline, 1 Year

30 Days
Change in liver Status
Change in markers of systemic Inflammation
Baseline, 1 Year
Change in Drinks/week in the Past 30 Days
Baseline, 30 Days
Change in Brain Function
Change in Neurocognitive Functions
Change in Neuroinflammation
Year 1
Change in gut microbiome

Trial Safety

Trial Design

0 Treatment Group

180 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 year

Who is running the clinical trial?

Florida International UniversityOTHER
84 Previous Clinical Trials
14,744 Total Patients Enrolled
Brown UniversityOTHER
408 Previous Clinical Trials
514,296 Total Patients Enrolled
28 Trials studying Alcohol Drinking
6,868 Patients Enrolled for Alcohol Drinking
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
711 Previous Clinical Trials
1,170,711 Total Patients Enrolled
238 Trials studying Alcohol Drinking
75,732 Patients Enrolled for Alcohol Drinking
University of MiamiOTHER
787 Previous Clinical Trials
384,091 Total Patients Enrolled
3 Trials studying Alcohol Drinking
874 Patients Enrolled for Alcohol Drinking
University of FloridaLead Sponsor
1,237 Previous Clinical Trials
698,305 Total Patients Enrolled
10 Trials studying Alcohol Drinking
1,492 Patients Enrolled for Alcohol Drinking
Ronald CohenPrincipal InvestigatorUniversity of Florida
Robert CookPrincipal InvestigatorUniversity of Florida

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.